Cavendish NanoTherapeutics

Location: 

Cambridgehsire, UK

Speaker: 

Thanos Mitrelias

Title: 

CEO

Primary Industry: 

Medical, Pharmaceuticals, Personal Care

Executive Summary: 

Cavendish NanoTherapeutics (CNT) offers advanced treatment systems aimed at the targeted eradication of cancer tumours. CNT’s proprietary systems are based on magnetic nanotechnology and utilize nanoparticles loaded with anticancer drugs and guided towards the tumour site to selectively destroy it in conjunction with electromagnetic excitation. Our clinical and pilot trials have demonstrated significant effects in the reduction of the size of a tumour and a 50% - 300% increase in the survival rates (on average) of patients with various types of cancer. For example, we have demonstrated a tripling in the survival rates of patients with stage IIIA lung cancer, when our treatment protocol is applied in conjunction with traditional therapies. We offer two products: a hyperthermia induction system MagTherm®, which has already been tested in clinical trials and NanoMagTherm® for induction of targeted hyperthermia combined with drug delivery using the magnetic nanoparticles. The range of tumours that can be selectively and locally attacked, demonstrates the wide applicability of our technology and hence, the wide range of multi-billion markets that can be addressed.